诊断学理论与实践 ›› 2025, Vol. 24 ›› Issue (03): 268-278.doi: 10.16150/j.1671-2870.2025.03.005
史曼曼1, 马毓华1, 郑金鑫2,3, 柯燕容1, 王语欣1, 刘剑2(), 王伟铭2(
)
收稿日期:
2025-01-28
接受日期:
2025-06-09
出版日期:
2025-06-25
发布日期:
2025-06-25
通讯作者:
王伟铭 E-mail:wwm11120@rjh.com.cn;刘剑 E-mail:lewis_963@163.com基金资助:
SHI Manman1, MA Yuhua1, ZHENG Jinxin2,3, KE Yanrong1, WANG Yuxin1, LIU Jian2(), WANG Weiming2(
)
Received:
2025-01-28
Accepted:
2025-06-09
Published:
2025-06-25
Online:
2025-06-25
摘要:
目的:评估1990年至2021年间,全球及中国不同年龄、性别、区域和社会人口指数(socio-demographic index,SDI)人群中2型糖尿病(type 2 diabetes,T2D)导致的慢性肾脏病(chronic kidney disease,CKD)(CKD-T2D)的疾病负担。方法:基于2021年全球疾病负担研究(Global Burden of Disease Study,GBD)数据,分析204个国家和地区的CKD-T2D发病率、患病率、死亡率和伤残调整寿命年(disability-adjusted life years,DALYs),计算绝对数值及其95%不确定性区间(uncertainty interval,UI)。结果:1990年至2021年间,全球CKD-T2D的疾病负担显著增加,2021年新发病例达2 012 024例(95% UI为1 857 800~2 154 288),较1990年增长167.2%(95%UI为153.5%~182.6%),年龄标准化发病率(age-standardized incidence rate,ASIR)为23.07/10万[95%UI为(21.40~24.72)/10万],较1990年上升21.0%(95%UI为15.0%~27.5%)。区域分析显示,北非和中东地区CKD-T2D的ASIR较高(42.802/10万)。相比于1990年,2021年中国的CKD-T2D发病人数显著增加,达354 157例(95% UI为321 265~382 784)粗发病率增长177.6%(95%UI为154.8%~205.5%),ASIR仅微升7.8%[95%UI为(-0.1%)~17.8%];其余指标的粗率增长,而年龄标准化率(age-standardized rate,ASR)下降。2021年,全球65~74岁人群的CKD-T2D发病最高[65~69岁人群新发364 163例(95%UI为272 571~475 468例),70~74岁人群新发366 045例(95%UI为286 728~459 891例)],其中男性负担高于女性[65~69岁,男性新发187 097例(95%UI为140 064~243 571例),女性新发177 066例(95%UI为132 338~231 769例);70~74岁,男性新发187 216例(95%UI为146 377~234 997例),女性新发178 830例(95%UI为140 938~224 801例)]。SDI分层显示,在1990年至2021年间,高SDI地区CKD-T2D的ASIR最高,且持续上升;而低SDI地区的CKD-T2D死亡率最高,且改善有限。高血糖、肥胖、高热量饮食和高血压是CKD-T2D的主要危险因素。结论:CKD-T2D仍是重大公共卫生问题,中低收入国家及老年、男性群体的疾病负担突出。中国的粗率攀升,但年龄标准化死亡率(age-standardized mortality rates,ASMR)和DALYs下降。
中图分类号:
史曼曼, 马毓华, 郑金鑫, 柯燕容, 王语欣, 刘剑, 王伟铭. 1990年至2021年全球及中国2型糖尿病导致的慢性肾脏病疾病负担及危险因素分析[J]. 诊断学理论与实践, 2025, 24(03): 268-278.
SHI Manman, MA Yuhua, ZHENG Jinxin, KE Yanrong, WANG Yuxin, LIU Jian, WANG Weiming. Global and Chinese burden of chronic kidney disease due to type 2 diabetes and associated risk factors from 1990 to 2021[J]. Journal of Diagnostics Concepts & Practice, 2025, 24(03): 268-278.
表1
2021、2019和1990年全球2型糖尿病相关慢性肾脏病的发病率、患病率、死亡率和伤残调整寿命年[n(95%UI)]
Items | Incidence | Prevalence | Mortality | DALYs |
---|---|---|---|---|
2021 | ||||
Number(×1 000) | 2 012.024 (1 857.800-2 154.288) | 107 559.955 (99 170.797-115 994.732) | 477.273 (401.541-565.951) | 11 278.935 (9 682.785-13 103.871) |
ASRs(/100 000) | 23.074 (21.403-24.724) | 1 259.627 (1 161.985-1 359.917) | 5.723 (4.826-6.792) | 131.082 (112.752-152.492) |
2019 | ||||
Number(×1 000) | 1 898.285 (1 756.086-2 033.895) | 103 692.703 (95 804.213-111 877.535) | 452.842 (384.289-535.796) | 10 649.449 (9 179.491-12 417.895) |
ASRs(/100 000) | 22.903 (21.208-24.569) | 1 261.314 (1 164.900-1 360.483) | 5.731 (4.833-6.798) | 130.187 (112.440-151.504) |
1990 | ||||
Number(×1 000) | 753.106 (680.930-826.928) | 58 105.268 (53 056.992-63 286.818) | 147.970 (124.179-176.413) | 4 122.919 (3 498.980-4 818.958) |
ASRs(/100 000) | 19.073 (17.285-20.835) | 1 327.225 (1 223.256-1 439.418) | 4.154 (3.504-4.936) | 105.710 (90.677-122.672) |
Percent change (2021 vs 2019) | ||||
Number | 6.0% (5.4%-6.6%) | 3.7% (3.4%-4.1%) | 5.4% (0.2%-10.9%) | 5.9% (1.3%-10.9%) |
ASRs | 0.7% (0.2%-1.3%) | -0.1% (-0.5%-0.2%) | -0.1 (-4.9%-5.0%) | 0.7% (-3.7%-5.4%) |
Percent change (2021 vs 1990) | ||||
Number | 167.2% (153.5%-182.6%) | 85.1% (78.1%-91.4%) | 222.5% (177.4%-253.8%) | 173.6% (140.5%-194.3%) |
ASRs | 21.0% (15.0%-27.5%) | -5.1% (-7.5%-3.0%) | 37.8% (19.2%-49.6%) | 24.0% (9.3%-33.0%) |
表2
2021、2019和1990年中国2型糖尿病相关慢性肾脏病的发病率、患病率、死亡率和伤残调整寿命年
Items | Incidence | Prevalence | Mortality | DALYs |
---|---|---|---|---|
2021 | ||||
Number(×1 000) | 354.157 (321.265-382.784) | 20 911.520 (19 184.463-2 2605.470) | 107.652 (84.626-134.047) | 2 537.070 (2 044.338-3 072.897) |
ASRs(/100 000) | 16.287 (14.921-17.529) | 1 053.915 (971.106-1 139.636) | 5.637 (4.462-6.998) | 122.149 (99.621-146.989) |
2019 | ||||
Number(×1 000) | 324.557 (293.012-350.843) | 20 100.997 (18 473.868-21 752.987) | 100.313 (81.544-119.984) | 2 376.638 (1 935.101-2 779.215) |
ASRs(/100 000) | 15.939 (14.489-17.164) | 1 051.714 (969.074-1 137.546) | 5.692 (4.573-6.835) | 122.509 (100.078-143.707) |
1990 | ||||
Number(×1 000) | 127.561 (112.718-142.654) | 11 890.522 (10 790.476-1 3078.708) | 43.537 (35.988-53.065) | 1 231.518 (1 022.061-1 492.725) |
ASRs(/100 000) | 15.109 (13.452-16.795) | 1 214.763 (1 109.345-1 320.704) | 6.825 (5.739-8.340) | 155.940 (131.157-188.264) |
Percent change(2021 vs 2019) | ||||
Number | 9.1% (6.9%-1.0%) | 4.0% (3.3%-4.8%) | 7.3% (-11.4%-31.0%) | 6.8% (-10.0%-26.2%) |
ASRs | 2.2% (0.5%-3.9%) | 0.2% (-0.4%-0.7%) | -1.0% (-17.5%-19.6%) | -0.3% (-15.8%-17.7%) |
Percent change(2021 vs 1990) | ||||
Number | 177.6% (154.8%-205.5%) | 75.9% (66.4%-85.1%) | 147.3% (89.3%-209.3%) | 106.0% (65.6%-148.7%) |
ASRs | 7.8% (-0.1%-17.8%) | -13.2%(-15.9%-10.9%) | -17.4%(-37.4%-1.9%) | -21.7% (-37.0%-5.7%) |
[1] | JHA R, LOPEZ-TREVINO S, KANKANAMALAGE H R, et al. Diabetes and renal complications: an overview on pathophysiology, biomarkers and therapeutic interventions[J]. Biomedicines, 2024, 12(5):1098. |
[2] | OOI Y G, SARVANANDAN T, HEE N K Y, et al. Risk prediction and management of chronic kidney disease in people living with type 2 diabetes mellitus[J]. Diabetes Metab J, 2024, 48(2):196-207. |
[3] |
VAN RAALTE D H, BJORNSTAD P, CHERNEY D Z I, et al. Combination therapy for kidney disease in people with diabetes mellitus[J]. Nat Rev Nephrol, 2024, 20(7):433-446.
doi: 10.1038/s41581-024-00827-z pmid: 38570632 |
[4] | DING X, LI X, YE Y, et al. Epidemiological patterns of chronic kidney disease attributed to type 2 diabetes from 1990-2019[J]. Front Endocrinol (Lausanne), 2024,15:1383777. |
[5] | Institute for Health Metrics and Evaluation. Global health data exchange[EB/OL]. 2021. http://ghdx.healthdata.org/gbd-results-tool. |
[6] | GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet,2024, 403(10440):2133-2161. |
[7] |
GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440):2100-2132.
doi: 10.1016/S0140-6736(24)00367-2 pmid: 38582094 |
[8] | Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2021 (GBD 2021) data resources[EB/OL]. 2024. https://ghdx.healthdata.org/gbd-2021. |
[9] | Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int, 2024, 105(4S):S117-S314. |
[10] |
GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440):2162-2203.
doi: 10.1016/S0140-6736(24)00933-4 pmid: 38762324 |
[11] | SOBAMOWO H, PRABHAKAR S S. The kidney in aging: physiological changes and pathological implications[J]. Prog Mol Biol Transl Sci, 2017,146:303-340. |
[12] | LYTVYN Y, BJORNSTAD P, VAN RAALTE D H, et al. The new biology of diabetic kidney disease-mechanisms and therapeutic implications[J]. Endocr Rev, 2020, 41(2):202-231. |
[13] | CLOTET-FREIXAS S, ZASLAVER O, KOTLYAR M, et al. Sex differences in kidney metabolism may reflect sex-dependent outcomes in human diabetic kidney disease[J]. Sci Transl Med, 2024, 16(737):eabm2090. |
[14] | PIANI F, MELENA I, TOMMERDAHL K L, et al. Sex-related differences in diabetic kidney disease: A review on the mechanisms and potential therapeutic implications[J]. J Diabetes Complications, 2021, 35(4):107841. |
[15] | LOEFFLER I, ZILLER N. Sex-related aspects in diabetic kidney disease-an update[J]. J Clin Med, 2023, 12(8):2834. |
[16] | BOWE B, XIE Y, LI T, et al. Changes in the US burden of chronic kidney disease from 2002 to 2016: An analysis of the Global Burden of Disease Study[J]. JAMA Netw Open, 2018, 1(7):e184412. |
[17] | SARAN R, ROBINSON B, ABBOTT K C, et al. US Renal Data System 2016 annual data report: epidemiology of kidney disease in the United States[J]. Am J Kidney Dis, 2017, 69(3Suppl 1):A7-A8. |
[18] | SINDHU D, SHARMA G S, KUMBALA D. Management of diabetic kidney disease: where do we stand? A narrative review[J]. Medicine (Baltimore), 2023, 102(13):e33366. |
[19] |
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults[J]. Lancet, 2024, 403(10431):1027-1050.
doi: 10.1016/S0140-6736(23)02750-2 pmid: 38432237 |
[20] | ZU C, LIU M, SU X, et al. Association of body weight time in target range with the risk of kidney outcomes in patients with overweight/obesity and type 2 diabetes mellitus[J]. Diabetes Care, 2024, 47(3):371-378. |
[21] | RUZE R, LIU T, ZOU X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments[J]. Front Endocrinol (Lausanne), 2023,14:1161521. |
[22] | ROSENFELD R M, KELLY J H, AGARWAL M, et al. Dietary interventions to treat type 2 diabetes in adults with a goal of remission: An expert consensus statement from the American College of Lifestyle Medicine[J]. Am J Lifestyle Med, 2022, 16(3):342-362. |
[23] | GALLARDO-GÓMEZ D, SALAZAR-MARTÍNEZ E, ALFONSO-ROSA R M, et al. Optimal dose and type of physical activity to improve glycemic control in people diagnosed with type 2 diabetes: A systematic review and meta-analysis[J]. Diabetes Care, 2024, 47(2):295-303. |
[24] | GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Di-sease Study 2017[J]. Lancet, 2018, 392(10159):1736-1788. |
[25] |
NCD Countdown 2030 collaborators. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4[J]. Lancet, 2018, 392(10152):1072-1088.
doi: S0140-6736(18)31992-5 pmid: 30264707 |
[26] |
NUGENT R, BERTRAM M Y, JAN S, et al. Investing in non-communicable disease prevention and management to advance the Sustainable Development Goals[J]. Lancet, 2018, 391(10134):2029-2035.
doi: S0140-6736(18)30667-6 pmid: 29627167 |
[1] | 张珂, 张唯一, 孙海天, 曹铭峰, 张新焕. 细胞失巢相关基因PDK4与2型糖尿病发病相关——基于生物信息的研究[J]. 诊断学理论与实践, 2025, 24(01): 27-34. |
[2] | 沈小钰, 沙莎, 殷蕾, 周纬, 茅幼英, 汪张娟, 孙燕, 吴燕. 合并蛋白尿的Ⅰ-Ⅱ期慢性肾脏病儿童动态血压变化的临床研究[J]. 诊断学理论与实践, 2024, 23(05): 531-536. |
[3] | 裴舟, 罗飞宏. 中国儿童糖尿病诊治进展[J]. 诊断学理论与实践, 2024, 23(05): 461-466. |
[4] | 范伯男, 李岩. 全球主要疾病负担及健康状况趋势分析——1990年至2021年全球疾病和伤害负担报告解读[J]. 诊断学理论与实践, 2024, 23(05): 474-483. |
[5] | 缪婕, 王巍, 赵雅洁, 张凤如, 沈琳辉. 老年男性2型糖尿病患者游离三碘甲状腺原氨酸水平与左心室舒张功能不全相关[J]. 诊断学理论与实践, 2024, 23(02): 155-161. |
[6] | 唐春花, 郭露, 李琼, 张莉莉. 2022年全球卒中数据报告解读[J]. 诊断学理论与实践, 2023, 22(03): 238-246. |
[7] | 钱莹, 马晓波, 高琛妮, 张春丽, 马骏, 张文, 陈晓农. 慢性肾脏病患者高尿酸血症与高血压的关联分析[J]. 诊断学理论与实践, 2023, 22(02): 160-165. |
[8] | 钱莹, 马晓波, 高琛妮, 陈孜瑾, 马骏, 俞海瑾, 张文, 陈晓农. 骨折风险评估工具在评估维持性血液透析患者骨折风险中的效能[J]. 诊断学理论与实践, 2023, 22(01): 50-57. |
[9] | 杨聚荣, 林利容. 慢性肾脏病患者妊娠的管理现状及策略[J]. 诊断学理论与实践, 2021, 20(02): 125-129. |
[10] | 范秋灵. 糖尿病肾病和非糖尿病慢性肾脏病患者应用钠-葡萄糖协同转运蛋白2抑制剂:预后评估及相关指南解读[J]. 诊断学理论与实践, 2021, 20(02): 130-137. |
[11] | 余舒文, 方正滢, 谢静远. 基因检测在慢性肾脏病诊治中的应用及进展[J]. 诊断学理论与实践, 2020, 19(06): 613-617. |
[12] | 李贵森. 2019年《中国慢性肾脏病矿物质和骨异常诊治指南》解读[J]. 诊断学理论与实践, 2020, 19(03): 229-231. |
[13] | 邓琳, 丁怡, 汪萍, 卞炳贤, 沈立松. 尿中性粒细胞明胶酶相关脂质运载蛋白/肌酐比值在2型糖尿病肾损伤的早期诊断及病情评估中的临床应用[J]. 诊断学理论与实践, 2019, 18(1): 61-65. |
[14] | 王媛媛, 范秋灵. 血清降钙素原在慢性肾脏病合并细菌感染患者中的临床价值[J]. 诊断学理论与实践, 2019, 18(03): 353-359. |
[15] | 张祎昀, 徐雷, 唐兆生, 陈英华, 窦琴, 冯波. 2型糖尿病合并戊型肝炎患者的临床特征分析[J]. 诊断学理论与实践, 2018, 17(05): 557-561. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||